Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Avaxia Biologics brings in $2.3mm with first close of Series A; adds more

Executive Summary

Avaxia Biologics Inc. (oral antibody therapeutics for gastrointestinal and metabolic diseases) raised $2.3mm in the first closing of its Series A financing. Lead investor Cherrystone Angels adds a board member and was joined by Boston Harbor Angels and undisclosed individuals.
Deal Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies